World's Best Scientists 2026 revealed!
Bernard Asselain

Bernard Asselain

D-Index & Metrics

Medicine

D-Index
86
Citations
39574
World Ranking
13889
National Ranking
449

Overview

Bernard Asselain is affiliated with the Institute Curie in France. Their research focuses primarily on medicine, with an emphasis on oncology, pulmonary and respiratory medicine, reproductive medicine, genetics, and cancer research. The scientist has contributed extensively to the understanding and treatment of cancer through numerous publications and collaborations.

Their recent published papers include:

  • Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial, 2023, Annals of Oncology
  • Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies, 2022, The Lancet Regional Health - Europe
  • LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial, 2021, Annals of Oncology
  • Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial, 2024, The Lancet Oncology
  • Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study, 2020, OncoImmunology

Frequent co-authors collaborating with Bernard Asselain include:

  • Fabien Reyal
  • Anne-Sophie Hamy
  • Élise Dumas
  • D. Debieuvre
  • Enora Laas

The scientist publishes regularly in several well-known venues, including:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Revue des Maladies Respiratoires Actualités
  • ESMO Open
  • bioRxiv (Cold Spring Harbor Laboratory)

Bernard Asselain's research covers multiple core topics within cancer and treatment research:

  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • Lung Cancer Treatments and Mutations
  • Cancer Risks and Factors
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Advanced Breast Cancer Therapies

Their work in oncology is complemented by a focus on pulmonary and respiratory medicine and reproductive medicine, reflecting an interdisciplinary approach to complex cancer-related health issues. The scientist's ongoing contributions have focused on advancing cancer therapies, including immunotherapies and targeted treatments like PARP inhibitors applied in ovarian cancer and other malignancies.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

    Henri Roché;Pierre Fumoleau;Marc Spielmann;Jean-Luc Canon

  • Age as prognostic factor in premenopausal breast carcinoma.

    A. de la Rochefordière;F. Campana;J. Fenton;J.R. Vilcoq

  • Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6

    S.M. Scholl;A. Fourquet;B. Asselain;J.Y. Pierga

  • Association of p53 mutations with short survival in colorectal cancer

    Richard Hamelin;Pierre Laurent-Puig;Sylviane Olschwang;Nathalie Jego

  • Stochastic Models of Tumor Latency and Their Biostatistical Applications

    A Yu Yakovlev;A D Tsodikov;B Asselain

  • Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes

    Roman Rouzier;Jean-Marc Extra;Jerzy Klijanienko;Marie-Christine Falcou

  • Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer

    P.A. Cabanes;R.J. Salmon;J.R. Vilcoq;J.C. Durand

  • Histopathologic risk factors in retinoblastoma: A retrospective study of 172 patients treated in a single institution

    F Khelfaoui;P Validire;A Auperin;E Quintana

  • Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer

    Frédérique Penault-Llorca;Fabrice André;Christine Sagan;Magali Lacroix-Triki

  • Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up.

    Christine Louis-Sylvestre;Krishna Clough;Bernard Asselain;Jacques René Vilcoq

  • Is obesity an independent prognosis factor in woman breast cancer

    Bilal Majed;Thierry Moreau;Kamel Senouci;Rémi J. Salmon

  • Regional copy number–independent deregulation of transcription in cancer

    Nicolas Stransky;Céline Vallot;Fabien Reyal;Isabelle Bernard-Pierrot

  • Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).

    Rémi Dendale;Livia Lumbroso-Le Rouic;Georges Noel;Loïc Feuvret

  • Survival and acquired genetic alterations in colorectal cancer.

    Pierre Laurent-Puig;Sylviane Olschwang;Olivier Delattre;Yourgos Remvikos

  • Contralateral breast cancer: annual incidence and risk parameters.

    P Broët;A de la Rochefordière;S M Scholl;A Fourquet

  • Familial Invasive Breast Cancers: Worse Outcome Related to BRCA1 Mutations

    Dominique Stoppa-Lyonnet;Yan Ansquer;Hélène Dreyfus;Chantal Gautier

  • Neoadjuvant chemotherapy in operable breast cancer

    S.M. Scholl;B. Asselain;T. Palangie;T. Dorval

Frequent Co-Authors

Alain Fourquet
Alain Fourquet Institute Curie
Véronique Diéras
Véronique Diéras Institute Curie
Anne Vincent-Salomon
Anne Vincent-Salomon Institute Curie
Jean-Yves Pierga
Jean-Yves Pierga Institute Curie
Xavier Sastre-Garau
Xavier Sastre-Garau Institute Curie
Mario Campone
Mario Campone Grenoble Alpes University
Suzette Delaloge
Suzette Delaloge Institut Gustave Roussy
Emmanuel Barillot
Emmanuel Barillot Institute Curie
François Doz
François Doz Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean becoming a doctor. There are several online degrees and alternative pathways that can lead to fulfilling roles in the healthcare field. Online programs, particularly in nursing, are making it easier than ever to start or advance your healthcare career from anywhere.

For those interested in advanced practice roles, finding the cheapest np school online can help reduce the financial burden while you earn the credentials needed to become a nurse practitioner. If you are just beginning, there are plenty of affordable online nursing programs that offer flexibility and a range of specializations.

Many registered nurses pursue further education, such as the cheapest online rn to bsn programs, to open up broader career opportunities and higher salaries. For those aiming at research or teaching positions, accredited online phd programs in nursing are also available at a lower cost than ever before.

With these diverse pathways, you can find the route that best fits your career goals, budget, and lifestyle—while still making a difference in healthcare.

Best Scientists Citing Bernard Asselain

Trending Scientists